Ropes & Gray advised Partners Group on the transaction. Partners Group, one of the largest firms in the global private markets industry, announced its acquisition of...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Acumen Pharmaceuticals on the transaction. Acumen Pharmaceuticals (Nasdaq:ABOS) (“Acumen”) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (Nasdaq:HALO) (“Halozyme”). Acumen will...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Goldfinch Bio on the deal. Goldfinch Bio announced an exclusive global license agreement with Karuna Therapeutics under which Karuna will have development, manufacturing...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented HUTCHMED on the deal. HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited announced an exclusive worldwide license agreement with Japan’s largest drugmaker Takeda...
You must be a Standard 1 Year member to access this content.
